170 related articles for article (PubMed ID: 18427122)
1. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility.
Lammerts van Bueren JJ; Bleeker WK; Brännström A; von Euler A; Jansson M; Peipp M; Schneider-Merck T; Valerius T; van de Winkel JG; Parren PW
Proc Natl Acad Sci U S A; 2008 Apr; 105(16):6109-14. PubMed ID: 18427122
[TBL] [Abstract][Full Text] [Related]
2. The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers. Implications for combination therapy with monoclonal antibody 806.
Gan HK; Walker F; Burgess AW; Rigopoulos A; Scott AM; Johns TG
J Biol Chem; 2007 Feb; 282(5):2840-50. PubMed ID: 17092939
[TBL] [Abstract][Full Text] [Related]
3. A molecular view of anti-ErbB monoclonal antibody therapy.
Leahy DJ
Cancer Cell; 2008 Apr; 13(4):291-3. PubMed ID: 18394550
[TBL] [Abstract][Full Text] [Related]
4. Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization.
Schmiedel J; Blaukat A; Li S; Knöchel T; Ferguson KM
Cancer Cell; 2008 Apr; 13(4):365-73. PubMed ID: 18394559
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations.
Perez-Torres M; Guix M; Gonzalez A; Arteaga CL
J Biol Chem; 2006 Dec; 281(52):40183-92. PubMed ID: 17082181
[TBL] [Abstract][Full Text] [Related]
6. Differential and synergistic effects of epidermal growth factor receptor antibodies on unliganded ErbB dimers and oligomers.
Kozer N; Kelly MP; Orchard S; Burgess AW; Scott AM; Clayton AH
Biochemistry; 2011 May; 50(18):3581-90. PubMed ID: 21495621
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms for kinase-mediated dimerization of the epidermal growth factor receptor.
Lu C; Mi LZ; Schürpf T; Walz T; Springer TA
J Biol Chem; 2012 Nov; 287(45):38244-53. PubMed ID: 22988250
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells.
Xu H; Yu Y; Marciniak D; Rishi AK; Sarkar FH; Kucuk O; Majumdar AP
Mol Cancer Ther; 2005 Mar; 4(3):435-42. PubMed ID: 15767552
[TBL] [Abstract][Full Text] [Related]
9. Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer.
Snyder LC; Astsaturov I; Weiner LM
Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S71-80. PubMed ID: 16336752
[TBL] [Abstract][Full Text] [Related]
10. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor.
Johns TG; Adams TE; Cochran JR; Hall NE; Hoyne PA; Olsen MJ; Kim YS; Rothacker J; Nice EC; Walker F; Ritter G; Jungbluth AA; Old LJ; Ward CW; Burgess AW; Wittrup KD; Scott AM
J Biol Chem; 2004 Jul; 279(29):30375-84. PubMed ID: 15075331
[TBL] [Abstract][Full Text] [Related]
11. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR.
Bremer E; Samplonius DF; van Genne L; Dijkstra MH; Kroesen BJ; de Leij LF; Helfrich W
J Biol Chem; 2005 Mar; 280(11):10025-33. PubMed ID: 15644326
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor: Structure-function informing the design of anticancer therapeutics.
Mitchell RA; Luwor RB; Burgess AW
Exp Cell Res; 2018 Oct; 371(1):1-19. PubMed ID: 30098332
[TBL] [Abstract][Full Text] [Related]
15. Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425.
Kamat V; Donaldson JM; Kari C; Quadros MR; Lelkes PI; Chaiken I; Cocklin S; Williams JC; Papazoglou E; Rodeck U
Cancer Biol Ther; 2008 May; 7(5):726-33. PubMed ID: 18424917
[TBL] [Abstract][Full Text] [Related]
16. In-depth biophysical analysis of interactions between therapeutic antibodies and the extracellular domain of the epidermal growth factor receptor.
Alvarenga ML; Kikhney J; Hannewald J; Metzger AU; Steffens KJ; Bomke J; Krah A; Wegener A
Anal Biochem; 2012 Feb; 421(1):138-51. PubMed ID: 22085444
[TBL] [Abstract][Full Text] [Related]
17. Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site.
Arteaga CL; Ramsey TT; Shawver LK; Guyer CA
J Biol Chem; 1997 Sep; 272(37):23247-54. PubMed ID: 9287333
[TBL] [Abstract][Full Text] [Related]
18. Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy.
Dowlati A; Nethery D; Kern JA
Mol Cancer Ther; 2004 Apr; 3(4):459-63. PubMed ID: 15078989
[TBL] [Abstract][Full Text] [Related]
19. Ligand-induced EGF receptor oligomerization is kinase-dependent and enhances internalization.
Hofman EG; Bader AN; Voortman J; van den Heuvel DJ; Sigismund S; Verkleij AJ; Gerritsen HC; van Bergen en Henegouwen PM
J Biol Chem; 2010 Dec; 285(50):39481-9. PubMed ID: 20940297
[TBL] [Abstract][Full Text] [Related]
20. Growth hormone-induced phosphorylation of epidermal growth factor (EGF) receptor in 3T3-F442A cells. Modulation of EGF-induced trafficking and signaling.
Huang Y; Kim SO; Jiang J; Frank SJ
J Biol Chem; 2003 May; 278(21):18902-13. PubMed ID: 12642595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
